CCS
RARE icon

Concentric Capital Strategies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Concentric Capital Strategies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,736
Closed -$594K – 370
2025
Q3 		$594K Buy
+19,736
New +$592K 0.03% 239

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Concentric Capital Strategies's RARE Position: Q4 2025 in Review

Concentric Capital Strategies sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 19,736 shares — an estimated $594K sold.

Concentric Capital Strategies first reported a position in RARE in Q3 2025 and held it in 1 quarter. The position peaked at $594K in Q3 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Concentric Capital Strategies reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Concentric Capital Strategies sold 19,736 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $594K.
  • Concentric Capital Strategies first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • Concentric Capital Strategies's Ultragenyx Pharmaceutical position peaked at $594K in Q3 2025.
  • 288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Concentric Capital Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.